Literaturverzeichnis

Chen, H., Chen, J., Zhang, F., Li, Y., Wang, R., Zheng, Q., Zhang, X., Zeng, J., Xu, F., & Lin, Y. (2022). Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in cardiovascular medicine, 9. https://doi.org/10.3389/fcvm.2022.964977

Deutscher Ärzteverlag GmbH. (2021). Herz-Kreislauf-Erkrankungen: US-Experten wollen ASS in der Primärprävention einschränken. Deutsches Ärzteblatt. https://www.aerzteblatt.de/nachrichten/128154/Herz-Kreislauf-Erkrankungen-US-Experten-wollen-ASS-in-der-Primaerpraevention-einschraenken

Kim, J. Y., Gum, S. N., Paik, J. K., Lim, H. H., Kim, K.-C., Ogasawara, K., Inoue, K., Park, S., Jang, Y., & Lee, J. H. (2008). Effects of nattokinase on blood pressure: A randomized, controlled trial. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 31(8), 1583–1588. https://doi.org/10.1291/hypres.31.1583

Kurosawa, Y., Nirengi, S., Homma, T., Esaki, K., Ohta, M., Clark, J. F., & Hamaoka, T. (2015). A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, 5(1). https://doi.org/10.1038/srep11601

Lampe, B. J., & English, J. C. (2016). Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 88, 87–99. https://doi.org/10.1016/j.fct.2015.12.025

Lawall, H., Diehm, C., Hoffmann, U., & Reinecke, H. (2015). Periphere arterielle Verschlusskrankheit: Epidemiologie, Komorbidität und Prognose. Deutsche medizinische Wochenschrift (1946), 140(24), 1798–1802. https://doi.org/10.1055/s-0041-107064

Li, L., Geraghty, O. C., Mehta, Z., & Rothwell, P. M. (2017). Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet, 390(10093), 490–499. https://doi.org/10.1016/s0140-6736(17)30770-5

NOAKs und gastrointestinale Blutungen: Symptomatik oft untypisch. (2019). Ärzte Zeitung; Verlagshaus der Ärzte. https://aerztezeitung.at/2019/oaz-artikel/medizin/noaks-gastrointestinale-blutungen/

Okamoto, A., Hanagata, H., Kawamura, Y., & Yanagida, F. (1995). Anti-hypertensive substances in fermented soybean, natto. Plant Foods for Human Nutrition (Dordrecht, Netherlands), 47(1), 39–47. https://doi.org/10.1007/bf01088165

Statistisches Bundesamt. (2023). Todesursachen. destatis.de. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/_inhalt.html

Weng, Y., Yao, J., Sparks, S., & Wang, K. (2017). Nattokinase: An oral antithrombotic agent for the prevention of cardiovascular disease. International Journal of Molecular Sciences, 18(3), 523. https://doi.org/10.3390/ijms18030523

World Health Organization. (2020). The top 10 causes of death. Who.int. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

Wu, H., Wang, Y., Zhang, Y., Xu, F., Chen, J., Duan, L., Zhang, T., Wang, J., & Zhang, F. (2020). Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. Redox Biology, 32(101500), 101500. https://doi.org/10.1016/j.redox.2020.101500